Importantly, this study revealed that pharmacological inactivation of MAGL robustly reduced TDP-43 production, providing the first evidence that inhibition of 2-AG metabolism prevents TBI-induced excessive formation of TDP-43, which, in turn, promotes recovery from the secondary injury, thus preventing cognitive decline [40]. The gene discussed is MGLL; the disease is Mental deterioration.